Relypsa   Report issue

Contributed to NME For profit Phase 2 Phase 4
Founded: Redwood City CA United States (2007)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2008
NCT02033317
First Marketed Drug
2015
patiromer (veltassa)
First NDA Approval
2015
patiromer (veltassa)
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Relypsa, Inc. | RELYPSA INC

Active Ingredients

Marketed Drugs (1)

patiromer (veltassa) (2015 NDA)

Drugs in Phase 4 Trials (2)

patiromer (veltassa) (12 trials)

spironolactone (aldactone) (5 trials)

Drugs in Phase 2 Trials (1)

losartan (cozaar) (1 trial)

Indications

Approved Indications


 

Hyperkalemia

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 4)

Diabetic Nephropathies (Phase 2)

Heart Failure (Phase 3)

Hyperkalemia (Phase 4)

Hypertension (Phase 2)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 3